Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma

The establishment of more effective treatments that can circumvent chemoresistance in Multiple Myeloma (MM) is a priority. Although bortezomib (BTZ) is one of the most potent proteasome inhibitors available, still possesses limitations related to dose limiting side effects. Several strategies have b...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Control Release
Main Authors: de la Puente, Pilar, Luderer, Micah J., Federico, Cinzia, Jin, Abbey, Gilson, Rebecca C., Egbulefu, Christopher, Alhallak, Kinan, Shah, Shruti, Muz, Barbara, Sun, Jennifer, King, Justin, Kohnen, Daniel, Salama, Noha Nabil, Achilefu, Samuel, Vij, Ravi, Azab, Abdel Kareem
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6056271/
https://ncbi.nlm.nih.gov/pubmed/29196043
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jconrel.2017.11.045
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados